Impact of the WHO Recommended Vitamin A Supplementation at Immunisation Contacts

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

9500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

High-dose vitamin A to children above 6 months of age reduces all-cause mortality by 23-30%. The WHO recommends vitamin A supplementation (VAS) with the first vaccine after 6 months of age. However, the effect of providing VAS with vaccines has never been investigated. We have hypothesised that the effect of VAS depends on the immune stimulus at the time of supplementation. Hence, the effect might vary depending on which type of vaccine it is given with. In particular, we hypothesised that VAS might be beneficial when given with measles vaccine but not when given with DTP vaccine. Normally the first vaccine after 6 months of age would be a measles vaccine, but many children come late for their DTP vaccinations and receive DTP alone or together with measles vaccine. Hence, it is important to study whether the effect of VAS is the same irrespective of the vaccine(s) administered at the same time.

Guinea-Bissau has not yet implemented the WHO vitamin A policy of providing VAS with vaccines, but plans to do so within the next years. Together with the Ministry of Health in Guinea-Bissau, the Bandim Health Project (BHP) in Guinea-Bissau will investigate the effect on mortality and morbidity of implementing the WHO vitamin A policy in Guinea-Bissau. This will be done in a large randomised trial.

BHP has a demographic surveillance system (DSS) which has followed a population of now more than 150,000 individuals for almost 30 years. Children will be randomised to receive VAS or placebo with their first vaccine after 6 months of age, and will be followed through the DSS to assess mortality and morbidity. Based on previous observations, the effects of VAS might differ according to sex and season. The interaction between VAS, sex, and season will also be studied in the present trial. By identifying situations where VAS may be beneficial, ineffective, or even harmful the study may contribute importantly to optimising the VAS policy for low-income countries.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin A Supplementation With Routine Childhood Vaccines and Mortality and Morbidity

NCT00168623

Mortality Morbidity

UNKNOWN PHASE4

Can BCG Vaccination at First Health-facility Contact Reduce Early Infant Mortality?

NCT04658680

Infant Mortality BCG

ACTIVE_NOT_RECRUITING PHASE4

Immunology of Non-specific Effects of Vaccine

NCT00168545

Measles Diphtheria Tetanus +1 more

COMPLETED PHASE4

The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age

NCT01306006

Mortality Vaccines

COMPLETED PHASE4

Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination

NCT00244673

Mortality Hospitalization Adverse Events

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mortality Morbidity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Vitamin A supplementation

Group Type ACTIVE_COMPARATOR

Vitamin A

Intervention Type BIOLOGICAL

The effect of vitamin A given with different vaccines will be studied

2

Placebo

Group Type PLACEBO_COMPARATOR

Vitamin A

Intervention Type BIOLOGICAL

The effect of vitamin A given with different vaccines will be studied

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin A

The effect of vitamin A given with different vaccines will be studied

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Urban area: 6-17-month-old children, presenting for vaccination at a health centre in the study area.
* Rural area: 6-23-month-old children who are missing one or more routine vaccinations when visited by our mobile team.